TJ(SH:600667) Shang Hai Zheng Quan Bao·2025-09-09 20:49Core Viewpoint - Chongqing Taiji Industrial (Group) Co., Ltd. has received approval for clinical trials of Semaglutide injection, a drug aimed at treating type 2 diabetes, which is a significant step towards its market entry [1][2]. Drug Basic Information - The drug name is Semaglutide injection, classified as a 3.3 biosimilar, and is intended for clinical trials in China [1]. - The approval allows for clinical trials focused on blood sugar control in adults with type 2 diabetes who have not achieved adequate control with existing treatments [2]. - Semaglutide acts as a GLP-1 receptor agonist, stimulating insulin production and reducing appetite, thus playing a crucial role in diabetes management and weight control [2]. Market Context - Currently, the only marketed Semaglutide injection in China is from the original developer, Novo Nordisk, which reported total revenue of $29.296 billion for the product in 2024 [2]. - The company’s product utilizes advanced yeast expression technology, aiming to match the quality and production scale of the original product [2]. R&D Investment - The company has invested approximately RMB 44.1834 million in the research and development of this project to date [3]. - Following the approval, the company will initiate clinical research and subsequently submit trial data to the National Medical Products Administration for production approval [3].